Cardiometabolic disease describes a combination of metabolic abnormalities that increases the risk of type 2 diabetes and cardiovascular diseases, including pathological changes such as insulin resistance, hyperglycemia, dyslipidemia, abdominal obesity, and hypertension, and environmental risk factors such as smoking, sedentary lifestyle, poor diet, and poverty. As the number of coronavirus disease 2019 (COVID-19) patients continues to rise, type 2 diabetes, cardiovascular disease, hypertension, and obesity, all components of, or sequelae of cardiometabolic disease, were identified among others as key risk factors associated with increased mortality in these patients. Numerous studies have been done to further elucidate this relationship between COVID-19 and cardiometabolic disease. Cardiometabolic disease is associated with both increased susceptibility to COVID-19 and worse outcomes of COVID-19, including intensive care, mechanical ventilation, and death. The proinflammatory state of cardiometabolic disease specifically obesity, has been associated with a worse prognosis in COVID-19 patients. There has been no evidence to suggest that antihypertensives and antidiabetic medications should be discontinued in COVID-19 patients but these patients should be closely monitored to ensure that their blood pressure and blood glucose levels are stable. Assessment of vaccination efficacy in cardiometabolic disease patients is also discussed.

心脏代谢疾病是指增加2型糖尿病和心血管疾病风险的代谢异常组合，包括胰岛素抵抗、高血糖、血脂异常、腹部肥胖和高血压等病理变化，以及吸烟、久坐生活方式、不良习惯等环境危险因素。饮食和贫穷。随着 2019 年冠状病毒病 (COVID-19) 患者数量持续增加，2 型糖尿病、心血管疾病、高血压和肥胖以及心脏代谢疾病的所有组成部分或后遗症等被确定为与 2019 年冠状病毒病 (COVID-19) 患者数量增加相关的关键危险因素。这些患者的死亡率。已经进行了大量研究来进一步阐明 COVID-19 与心脏代谢疾病之间的这种关系。心脏代谢疾病与对 COVID-19 的易感性增加和 COVID-19 的更差结果相关，包括重症监护、机械通气和死亡。心脏代谢疾病（特别是肥胖）的促炎症状态与 COVID-19 患者的预后较差有关。尚无证据表明 COVID-19 患者应停用抗高血压和抗糖尿病药物，但应密切监测这些患者，以确保其血压和血糖水平稳定。还讨论了心脏代谢疾病患者的疫苗接种效果评估。